Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $6.7100 (-0.22%) ($6.7100 - $6.7100) on Tue. Jul. 6, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.05% (three month average) | RSI | 30 | Latest Price | $6.7100(-0.22%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.6% a day on average for past five trading days. | Weekly Trend | AUTL declines -5.2% a week on average for past two weeks. | Market Behavior | Rotation from value to growth for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(55%) ARKG(49%) ARKK(48%) IWC(48%) IWO(48%) | Factors Impacting AUTL price | AUTL will decline at least -3.025% in a week (0% probabilities). VIXM(-30%) VXX(-28%) SHY(-18%) TLT(-17%) BNDX(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.025% (StdDev 6.05%) | Hourly BBV | -0.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.07 | 5 Day Moving Average | $6.71(0%) | 10 Day Moving Average | $6.81(-1.47%) | 20 Day Moving Average | $7.07(-5.09%) | To recent high | -15.5% | To recent low | 33.9% | Market Cap | $351m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |